

BY FAX AND CONFIRMATORY COPY BY HAND DELIVERY

October 31, 2011

The Secretary
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

Dear Sir,

Pursuant to Clause 41 of the Listing Agreement, we enclose herewith our Unaudited Financial Results along with limited review report of the Company's Auditors for the 2nd Quarter and half year ended 30th September, 2011, which was taken on record at the Meeting of the Board of Directors of the Company held today.

We are also enclosing herewith a press release issued by the Company in respect of its Q2 unaudited financial Results.


We also wish to inform you that, the Board has declared an interim dividend of 50% (Re. 1/- per share) for the financial year 2011-12.

Kindly note that vide our letter dated 17th October, 2011, we have already informed you that 7th November, 2011 has been fixed as the Record Date for ascertaining the members entitlement of above interim dividend now declared.

This is for your information and record.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish P. Kamath
Company Secretary

Encl : a/a

Cc: The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Ipca Laboratories Ltd.

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India

T: +91 22 6647 4444 F: +91 22 2868 6613 www.ipcalabs.com



Ipca Laboratories Limited

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (W), Mumbai-400 067.


UNAUDITED FINANCIAL RESULTS

(Rs. Crores)

Particulars	Quarter Ended		Half Year Ended		Year Ended 31.3.2011 (Audited)
	30.9.2011	30.9.2010	30.9.2011	30.9.2010	
Gross Sales	636.93	531.92	1179.38	958.99	1920.94
Less : Excise Duty and Sales Tax	18.91	17.63	35.03	30.20	55.02
Net Sales	618.02	514.29	1144.35	928.79	1865.92
Other Operating Income	5.48	4.00	9.05	7.48	15.18
Total Income	623.50	518.29	1153.40	936.27	1881.10
Expenditure					
a) (Increase)/decrease in stock in trade and work in progress	(5.22)	(1.95)	(16.56)	(15.52)	(48.69)
b) Materials consumption	227.17	184.27	426.16	349.57	721.62
c) Purchase of traded goods	21.51	22.12	44.23	45.21	94.64
d) Employees Cost	72.80	69.98	156.37	135.73	261.59
e) Depreciation / Amortisation	17.58	13.68	32.99	26.56	55.43
f) Manufacturing and other expenditure	149.20	125.87	289.98	232.05	473.45
Total Expenditure	483.04	413.97	933.17	773.60	1558.04
Profit from operations before Other Income, Foreign Exchange transactions/translations (gain)/ loss, Interest & Tax	140.46	104.32	220.23	162.67	323.06
Other Income	2.64	2.71	5.29	5.22	8.44
Profit before Foreign Exchange transactions/ translations (gain)/loss, Interest & Tax	143.10	107.03	225.52	167.89	331.50
Foreign Exchange transactions/translations (gain) / loss	27.15	(28.84)	18.05	(25.91)	(43.34)
Financial cost	11.76	8.16	20.09	14.95	31.14
Profit before tax	104.19	127.71	187.38	178.85	343.70
Tax Expense (including Deferred Tax and short/(excess) provision of Tax for earlier years)	26.23	33.70	47.75	46.00	78.37
Net Profit after tax (before exceptional item)	77.96	94.01	139.63	132.85	265.33
Exceptional item:					
Provision for investment in subsidiaries	-	-	-	-	9.96
Net Profit (after exceptional item)	77.96	94.01	139.63	132.85	255.37
Paid-up equity share capital (Face value of Rs.2/- each)	25.14	25.04	25.14	25.04	25.14
Reserves excluding revaluation reserve	-	-	-	-	1028.72
Earnings per share (Rs.) (before exceptional item)					
Basic	6.20	7.51	11.11	10.61	21.16
Diluted	6.20	7.49	11.10	10.59	21.15
Earnings per share (Rs.) (after exceptional item)					
Basic	6.20	7.51	11.11	10.61	20.36
Diluted	6.20	7.49	11.10	10.59	20.35
Debt Service coverage ratio (DSCR) (No. of times) #	-	-	4.79	5.37	5.98
Interest service coverage ratio (ISCR) (No. of times) ##	-	-	14.27	17.86	15.67
Aggregate of public shareholding					
- Number of shares	67818979	67345965	67818979	67345965	67820715
- Percentage of shareholding	53.95%	53.78%	53.95%	53.78%	53.95%
Promoters and Promoter group shareholding					
a) Pledged / Encumbered					
- Number of Shares	7647900	8658182	7647900	8658182	7841082
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	13.21%	14.96%	13.21%	14.96%	13.55%
- Percentage of Shares (as a % of the total share capital of the Company)	6.08%	6.91%	6.08%	6.91%	6.24%
b) Non - encumbered					
- Number of Shares	50239526	49223508	50239526	49223508	50044608
- Percentage of Shares (as a % of the total share holding of promoter and promoter group)	86.79%	85.04%	86.79%	85.04%	86.45%
- Percentage of Shares (as a % of the total share capital of the Company)	39.97%	39.31%	39.97%	39.31%	39.81%

DSCR = [(Profit after tax before exceptional items + depreciation + interest on long term debts) / (Interest & Principal repayment of long term debts during the period)]

ISCR = [(Profit before tax + depreciation + gross interest) / Gross interest]



UNAUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2011

(Rs. Crores)

Sr. No.	Particulars	Standalone		Standalone
		30.09.2011	30.09.2010	31.03.2011 (Audited)
1	Shareholders' Funds			
	a) Capital	25.14	25.04	25.14
	b) Share Application money pending allotment	-	0.01	-
	c) Reserves and Surplus	1139.94	950.29	1028.72
2	Loan Fund	590.50	481.70	530.81
3	Deferred Tax Liability	89.93	85.71	80.73
	Total	1845.51	1542.75	1665.40
4	Fixed Assets	912.38	733.22	810.97
5	Investments	63.37	56.80	48.94
6	Current Assets, Loans and Advances			
	a) Inventories	514.76	383.98	462.51
	b) Sundry Debtors	503.72	544.08	466.31
	c) Cash and Bank balances	33.58	2.91	8.44
	d) Loans and Advances	152.07	100.29	115.99
	Less : Current Liabilities and Provisions			
	a) Liabilities	322.09	263.45	205.76
	b) Provisions	12.28	15.08	42.00
7	Miscellaneous Expenditure(Not written off)	-	-	-
	Total	1845.51	1542.75	1665.40

Notes:

1. The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on October 31, 2011.
2. The Auditors of the Company have carried out the limited review of the above unaudited financial results in terms of clause 41 of the Listing Agreement.
3. The Board has declared an interim dividend of Re. 1/- per share (50%) for the financial year 2011-12 for which 7th November, 2011 has been fixed as the record date for members' entitlement of Interim dividend.
4. During the quarter, the Company's wholly owned subsidiary M/s. Ipca Laboratories U.K. Ltd acquired 100% share holding of M/s. Onyx Research Chemicals Ltd., U.K., holding company of M/s. Onyx Scientific Ltd., U.K.
5. Subject to necessary approvals, the Board has decided to merge M/s. Tonira Pharma Ltd. with the Company w.e.f. 1st April, 2011. The shares exchange ratio fixed for the merger is 6 equity shares of the Company for every 100 equity shares of M/s. Tonira Pharma Ltd. No effect for the merger is given in the accounts pending the necessary approval.
6. The entire operations of the Company relate to only one segment viz. 'Pharmaceuticals'.
7. Previous year's figures have been regrouped, wherever necessary.
8. During the quarter, 11 investor grievances were received and all were disposed off. No grievances were pending either at the beginning or at the end of the quarter.



By order of the Board
For Ipca Laboratories Limited

[Signature]

Place : Mumbai
Date : October 31, 2011

A.K. Jain
Jt. Managing Director

Ipca's brand identity has evolved. Modern, dynamic yet warm and friendly, energetic yet sensitive, our new identity is an expression of the Ipca of today.

Natvarlal Vepari & Co.

CHARTERED ACCOUNTANTS

Oricon House, 4th Floor, 12, K. Dubash Marg, Mumbai-400 023. • Tel : 6752 7100 • Fax : 6752 7101 • E-Mail : nvc@nvc.in

Report on Limited Review

To
The Board of Directors
Ipca Laboratories Limited,
Mumbai.

We have reviewed the accompanying statement of un-audited financial results of Ipca Laboratories Limited for the period ended 30th September 2011 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement for Equity Shares and Clause 4 of the Listing Agreement for Debt Securities including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Natvarlal Vepari & Co.
Chartered Accountants
Firm Registration No. 106971W



N Jayendran
Partner

M. No. - 40441

Mumbai, Dated: - October 31, 2011

PRESS RELEASE

Ipca Laboratories Q2 FY12 Results

Net Total Income at Rs. 626.14 Crores, up by 20%

EBITDA at Rs. 158.04 Crores, up by 34%

EBITDA margin @ 25.35% in Q2 FY12 as against 22.77% in Q2 FY11

Net Profit at Rs. 77.96 Crores, down by 17%

(on account of forex transaction / translation loss of Rs. 27.15 Crores in Q2 FY12 as against forex transaction / translation gain of Rs. 28.84 Crores in Q2 FY11)

Interim Dividend of Re. 1/- per share (50%) declared

Mumbai, India, October 31, 2011: Ipca Laboratories Limited today announced its unaudited financial results for the second quarter ended 30th September, 2011 of the financial year 2011-12.

Key Highlights of Q2 FY12

- Net Total Income at Rs. 626.14 crores in Q2 FY12 as against Rs. 521.00 crores in Q2 FY11, growth of 20%.
- Export Income at Rs. 353.19 crores in Q2 FY12 as against Rs. 251.53 crores in Q2 FY11, growth of 40%.
- EBITDA at Rs. 158.04 crores in Q2 FY12 as against Rs. 118.00 crores in Q2 FY11, growth of 34%.
- EBITDA margin @ 25.35% in Q2 FY12 as against 22.77% in Q2 FY11.
- Net Profit at Rs. 77.96 crores in Q2 FY12 as against Rs. 94.01 crores in Q2 FY11, de-growth of 17%. The de-growth in net profit is on account of forex transaction / translation loss of Rs.27.15 crores in Q2 FY12 as against forex transaction / translation gain of Rs. 28.84 crores in Q2 FY11.
- EPS of Rs. 6.20 in Q2 FY12 as against Rs. 7.49 in Q2 FY11.
- Interim Dividend of Re. 1/- per share (50%) declared.



Revenue Break-up – Q2 FY12

Formulations:

- Total Revenue from formulations business at Rs. 489.69 crores in Q2 FY12 as against Rs. 397.04 crores in Q2 FY11, growth of 23%.
- Revenue from Indian formulations business at Rs. 229.21 crores in Q2 FY12 as against Rs. 221.94 crores in Q2 FY11, growth of 3%.
- Revenue from export formulations business at Rs. 260.48 crores in Q2 FY12 as against Rs. 175.10 crores in Q1 FY11, growth of 49%.

Active Pharmaceutical Ingredients (APIs)

- Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 128.33 crores in Q2 FY12 as against Rs. 117.27 crores in Q2 FY11, growth of 9%.
- Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 35.62 crores in Q2 FY12 as against Rs. 40.84 crores in Q2 FY11, de-growth of 13%.
- Revenue from export Active Pharmaceutical Ingredients (APIs) business at Rs. 92.71 crores in Q2 FY12 as against Rs. 76.43 crores in Q2 FY11, growth of 21%.

Key Highlights of H1 FY12

- Net Total Income at Rs. 1158.69 crores in H1 FY12 as against Rs. 941.49 crores in H1 FY11, growth of 23%.
- Export Income at Rs. 649.85 crores in H1 FY12 as against Rs. 461.85 crores in H1 FY11, growth of 41%.
- EBITDA at Rs. 253.22 crores in H1 FY12 as against Rs. 189.23 crores in H1 FY11, growth of 34%.
- EBITDA margin @ 21.95% in H1 FY12 as against 20.21% in H1 FY11.
- Net Profit at Rs. 139.63 crores in H1 FY12 as against Rs. 132.85 crores in H1 FY11, growth of 5%. The lower growth in net profit is on account of forex transaction / translation loss of Rs. 18.05 crores in H1 FY12 as against forex transaction / translation gain of Rs. 25.91 in H1 FY11.
- EPS of Rs. 11.10 in H1 FY12 as against Rs. 10.59 in H1 FY11.



Revenue Break-up – H1 FY12

Formulations:

- Total Revenue from formulations business at Rs. 885.24 crores in H1 FY12 as against Rs. 687.27 crores in H1 FY11, growth of 29%.
- Revenue from Indian formulations business at Rs. 418.18 crores in H1 FY12 as against Rs. 390.14 crores in H1 FY11, growth of 7%.
- Revenue from export formulations business at Rs. 467.06 crores in H1 FY12 as against Rs. 297.13 crores in H1 FY11, growth of 57%.

Active Pharmaceutical Ingredients (APIs)

- Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 259.11 crores in H1 FY12 as against Rs. 241.52 crores in H1 FY11, growth of 7%.
- Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs.76.32 crores in H1 FY12 as against Rs. 76.80 crores in H1 FY11, de-growth of 1%.
- Revenue from export Active Pharmaceutical Ingredients (APIs) business at Rs.182.79 crores in H1 FY12 as against Rs. 164.72 crores in H1 FY11, growth of 11%.
- Till date, the Company has filed 24 ANDAs with US-FDA out of which 12 ANDAs are granted.
- 60 DMFs are also filed with US-FDA for Active Pharmaceutical Ingredients (APIs).

Q2 FY12 at a glance

(Rs. Crores)			
2 nd Quarter ended	30.09.2011	30.09.2010	Growth
Net Total Income	626.14	521.00	20%
Export Income	353.19	251.53	40%
EBITDA	158.04	118.00	34%
Profit before Forex (gain) / loss and tax	131.34	98.87	33%
Forex (gain) / loss	27.15	(28.84)	-
Net Profit after Forex (gain) / loss and tax	77.96	94.01	-17%
Earnings per share of Rs. 2/- each (Rs.)	6.20	7.49	-17%



ipca Laboratories Ltd.

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India

T: +91 22 6647 4444 F: +91 22 2868 6613 www.ipcalabs.com

H1 FY12 at a glance

(Rs. Crores)			
Half Year ended	30.09.2011	30.09.2010	Growth
Net Total Income	1158.69	941.49	23%
Export Income	649.85	461.85	41%
EBITDA	253.22	189.23	34%
Profit before Forex (gain) / loss and tax	205.43	152.94	34%
Forex (gain) / loss	18.05	(25.91)	-
Net Profit after Forex (gain) / loss and tax	139.63	132.85	5%
Earnings per share of Rs. 2/- each (Rs.)	11.10	10.59	5%

About Ipca Laboratories:

Ipca Laboratories is a fast growing pharmaceutical major, with a strong thrust on exports. Exports to over 110 countries, now account for 56% of Company's income. Ipca Laboratories is vertically integrated and produces finished dosage forms and Active Pharmaceutical Ingredients.



A. K. Jain
 Joint Managing Director

Encl: Unaudited Financial Results

Contact Information:

Harish P. Kamath, Sr. V.P. Legal & Company Secretary at harish@ipca.co.in or on +91-22-66474644



Ipca Laboratories Ltd.

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India

T: +91 22 6647 4444 F: +91 22 2868 6613 www.ipcalabs.com